Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Cutaneous T-Cell Lymphoma Clinical Trial

Official title:

A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00490776
• Other study ID #: CLBH589B2212
• Status: Terminated
• Phase: Phase 2
• Start date: July 5, 2007
• Est. completion date: September 22, 2009

Study information

• Verified date: August 2021
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: September 22, 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Written informed consent obtained prior to any screening procedures

2. Age greater than or equal to 18 years old

3. Participants with biopsy-confirmed stages IB-IVA mycosis fungoides or Sézary syndrome (SS). Participants with SS who have bone marrow involvement are also eligible. Participants with transformed CTCL are eligible

4. Participants must have been treated with an HDAC inhibitor given for the treatment of CTCL. Participants must have had disease progression on or following treatment with an HDAC inhibitor. Participants are also eligible if they had an inadequate response to an HDAC inhibitor defined as stable disease as the best response after at least 3 months of therapy. Participants previously treated with an HDAC inhibitor are also eligible if they experienced intolerance due to adverse events.

5. Baseline multiple-gated acquisition scan (MUGA) or echocardiogram must have demonstrated left ventricular ejection fraction (LVEF) = the lower limit of the institutional normal

6. ECOG performance status = 2

Exclusion criteria:

1. Participants with a history of visceral disease including central nervous system (CNS) involvement (i.e. stage IVB CTCL). Note, participants who have SS with bone marrow involvement are eligible

2. Impaired cardiac function

3. Concomitant use of drugs with a risk of causing torsades de pointes

4. Participants who have received chemotherapy or any investigational drug or undergone major surgery = 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy

5. Less than 3 months since prior electron beam therapy

6. Women who are pregnant or breast feeding, or women of childbearing potential (WOCBP) not willing to use a double method of contraception during the study and 3 months after the end of treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Related Conditions & MeSH terms

• Cutaneous T-Cell Lymphoma
• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Cutaneous

Intervention

Drug:
• Panobinostat
Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.

Locations

Country	Name	City	State
United States	Medical College of Georgia	Augusta	Georgia
United States	University of Colorado Health Sciences Center/Anschutz Cancer Pavillion	Aurora	Colorado
United States	University of Alabama at Birmingham/ The Kirklin Clinic	Birmingham	Alabama
United States	Our Lady of Mercy Medical Center/Comprehensive Cancer Center	Bronx	New York
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	Rush Presbyterian Hospital/St. Luke's Medical Center	Chicago	Illinois
United States	The Jones Clinic	Germantown	Tennessee
United States	MD Anderson Cancer Center/University of Texas	Houston	Texas
United States	UCLA Medical Center School of Medicine/ Dpt of Hematology-Oncology	Los Angeles	California
United States	Florida Academic Dermatology Centers	Miami	Florida
United States	NYU Clinical Cancer Center	New York	New York
United States	Nebraska Medical Center	Omaha	Nebraska
United States	University of Pittsburg Medical Center	Pittsburgh	Pennsylvania
United States	Craig Okada	Portland	Oregon
United States	St. Louis University Cancer Cennter	Saint Louis	Missouri
United States	Seattle Cancer Care Alliance	Seattle	Washington
United States	University of Oklahoma-Tulsa	Tulsa	Oklahoma
United States	Wake University Health Sciences	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR) in Participants With Resistant Cutaneous T-Cell Lymphoma (CTCL) Treated With Oral Panobinostat by Using the Modified Severity-Weighted Assessment Tool (mSWAT)	ORR was defined as the percentage of participants with best overall response (OR) of complete response (CR) or partial response (PR) based on mSWAT score, (OR = CR + PR). mSWAT score represents the product of the percentage total body surface area (%TBSA) involvement of each lesion type (patch, plaque, and tumor or ulceration), multiplied by a weighting factor: modified SWAT score = (patch %TBSA x 1) + (plaque %TBSA x 2) + (tumor or ulcer %TBSA x 4). The sum of these 3 numbers gave the modified SWAT score, on a 0 (no lesions) to 400 (lesions covering all areas) scale. CR based on mSWAT score was defined as the absence of skin disease. PR was defined as = 50% decrease of the modified SWAT score compared to the Baseline score.	From first dose of study drug up to disease progression or death, (up to approximately 2 years)
Secondary	Response Rate of Participants With Refractory CTCL Using the Physician's Global Assessment of Clinical Condition (PGA)	Response rate was defined as the percentage of participants with CR or PR based on PGA scale. PGA is a 7-point grading scale for the investigator's assessment of the overall extent of improvement or worsening of the participant's disease as compared to Baseline. CR corresponds to Grade 0 (Completely clear) on PGA scale and was defined as no evidence of disease; 100% improvement. PR corresponds to Grade 2 (marked improvement) on PGA scale and was defined as significant improvement (=75% - <90%); some evidence of disease remains.	From first dose of study drug up to disease progression or death, (up to approximately 2 years)
Secondary	Response Rate in Participants With Refractory CTCL Using Modified Skin Score	Response rate was defined as the percentage of participants with CR or PR based on mSWAT skin score. mSWAT score represents the product of the %TBSA involvement of each lesion type (patch, plaque, and tumor or ulceration), multiplied by a weighting factor: mSWAT score = (patch %TBSA x 1) + (plaque %TBSA x 2) + (tumor or ulcer %TBSA x 4). The sum of these 3 numbers gave the modified SWAT score, on a 0 (no lesions) to 400 (lesions covering all areas) scale. CR based on mSWAT score was defined as the absence of skin disease. PR was defined as = 50% decrease of the modified SWAT score compared to the Baseline score.	From first dose of study drug up to disease progression or death, (up to approximately 2 years)
Secondary	Responses in Index Lesions in Participants With Refractory CTCL by Lesion Measurements With Photographic Supporting Documentation	Index lesions in each participant were selected as four to six of the prominent lesions amenable to bi-dimensional measurements. The longest diameter and its perpendicular measurement were used to determine the surface area and a weighted sum was determined as: Lesion 1 + lesion 2 + … + lesions 6 = Total sum of weighted score where Lesion 1: cm^2 x [1 (for patch); 2 (for plaque); 4 (for tumor or ulcer)]; Lesion 2: cm^2 x [1 (for patch); 2 (for plaque); 4 (for tumor or ulcer)]; Lesion 6: cm^2 x [1 (for patch); 2 (for plaque); 4 (for tumor or ulcer)]. These lesions were photographed at Baseline and at the time of response determined by either mSWAT or PGA	From first dose of study drug up to disease progression or death (up to approximately 2 years)
Secondary	ORR of Participants With Resistant CTCL Treated With Oral Panobinostat by Using the Modified PGA to Assess Skin Disease and the Evaluation of Disease in the Viscera, Lymph Nodes and Blood (Circulating Sézary Syndrome Cells)	ORR was defined as the percentage of participants with best OR of CR or PR based on PGA scale (OR = CR + PR). The PGA is a 7-point grading scale for the investigator's assessment of the overall extent of improvement or worsening of the participant's disease as compared to Baseline. CR corresponds to Grade 0 (completely clear) of PGA scale and was defined as no evidence of disease; 100% improvement. PR corresponds to Grade 2 (marked improvement) of PGA scale and was defined as significant improvement (=75%-<90%); some evidence of disease remains.	From first dose of study drug up to disease progression or death, (up to approximately 2 years)
Secondary	Duration of Response (DOR)	DOR was defined as the time from first documented evidence of CR or PR until the earliest date of documented progression or death due to any cause among participants who achieved a confirmed CR or PR. The DOR was calculated in two ways. The DOR among responders only included participants who responded to the drug. The overall DOR included non-responders as having a DOR of zero days.	From first dose of study drug up to disease progression or death, (up to approximately 2 years)
Secondary	Time to Response (TTR)	TTR was defined as the time from the start of treatment until the first documented evidence of CR or PR among participants who achieved a confirmed CR or PR.	From first dose of study drug up to study completion (approximately 2 years)
Secondary	Progression-Free Survival (PFS)	PFS was defined as the time from the start of treatment until the earliest date of disease progression or death due to any cause, if sooner.	From first dose of study drug up to disease progression or death, (up to approximately 2 years)